Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Russell 2000 Stocks to Buy Right Now. On January 20, Tiago Fauth from Wells Fargo reiterated a Buy rating on the stock and raised the price target to $88 from $84. Earlier on January 12, TD Cowen also reiterated a Buy rating on the stock with a $95 price target.

​Fauth from Wells Fargo noted that Attruby posted a strong revenue beat in Q4. As a result, Wells Fargo raised 2026 estimates by 10%. The firm noted that it expects some seasonal volatility in Q1 2026, but expects strong quarter-over-quarter growth during the rest of the year.

​Similarly, TD Cowen also highlighted that Attruby generated a revenue of roughly $146 million in the fourth quarter. The firm highlighted that this exceeded the expectations by 9%. Importantly, the quarter marked the completion of the first year for the drug, where it generated more than $362 million. The firm remains optimistic about the first-quarter data, as the company will reveal the outcome of BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Infi program. TD Cowen expects the data to support a best-in-class profile.

​BridgeBio Pharma, Inc. (NASDAQ:BBIO) develops therapies for genetic diseases and cancers, supporting its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT), which advances precision cancer treatments targeting key oncogenes, such as RAS and PI3K, into clinical trials.

While we acknowledge the potential of BBIO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BBIO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.